Andrea Lobo, PhD, science writer —

A greater increase in body mass index (BMI), a measure of body fat, from ages 1 through 6 in boys with cystic fibrosis (CF) results in the early production of sex hormones, called adrenarche, according to a small study. Boys with early adrenarche had…

The nasal microbiome — the community of microorganisms that live in the nose — obtained through nasal lavage correlates with inflammation in the nose and sinuses of children with cystic fibrosis (CF),  a study indicates. The effect wasn’t observed when samples were obtained by a nasal…

Clarametyx Biosciences has completed a $33 million financing round to support its development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial infections in people with cystic fibrosis (CF). The funding contributed to the start of a Phase 1b/2a clinical trial of CMTX-101 as an adjunct therapy to standard-of-care…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to BX004, BiomX’s inhaled phage therapy being developed for chronic Pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis (CF). The designation seeks to encourage new therapies for rare diseases, those affecting fewer than 200,000…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) improved the pancreatic function of two women with cystic fibrosis (CF), allowing them to stop their pancreatic enzyme replacement therapy (PERT). The women each had a combination of an F508del mutation, which leads to the abnormal folding of the CFTR protein, and…

Mental health issues — namely, attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) — in children with cystic fibrosis (CF) may be associated with a poorer adherence to treatments, more hospitalizations, and higher use of antibiotics, according to a recent report. “These initial findings suggest that mental health screening…

Blood levels of an indicator of diabetes, glycated hemoglobin (HbA1c), fell within the first year that cystic fibrosis (CF) patients were treated with Kaftrio, the triple combination therapy marketed as Trikafta in North America, according to a study of patients in Denmark. But among those with CF-related…

Treatment with CFTR modulators lessened the need for opioids and other painkillers in people with cystic fibrosis (CF), and led to a more stable use of psychotropics among those being treated for their mental health, a real-world data study from Australia reported. These therapies also led to increases…

ViaNautis has secured $25 million in financing to advance work with polyNaut, its delivery platform for genetic and other treatments. The platform is designed to deliver a range of therapies into difficult-to-penetrate tissues. According to the company, the money raised will help to support polyNaut’s use…

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improved lung function and nutritional status in two adults with cystic fibrosis (CF) caused by the rare mutation M1101K, according to two cases described in Canada. “Our cases not only demonstrate the therapeutic benefit of [Trikafta] in individuals with non-F508del…